Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Common Equity (2016 - 2025)

Haemonetics (HAE) has 16 years of Common Equity data on record, last reported at $911.5 million in Q4 2025.

  • For Q4 2025, Common Equity rose 0.51% year-over-year to $911.5 million; the TTM value through Dec 2025 reached $911.5 million, up 0.51%, while the annual FY2025 figure was $820.8 million, 14.49% down from the prior year.
  • Common Equity reached $911.5 million in Q4 2025 per HAE's latest filing, up from $849.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $960.0 million in Q1 2024 and bottomed at $677.1 million in Q3 2021.
  • Average Common Equity over 5 years is $824.9 million, with a median of $835.0 million recorded in 2025.
  • Peak YoY movement for Common Equity: grew 24.62% in 2021, then fell 14.49% in 2025.
  • A 5-year view of Common Equity shows it stood at $698.5 million in 2021, then increased by 11.08% to $776.0 million in 2022, then increased by 21.57% to $943.3 million in 2023, then fell by 3.86% to $906.9 million in 2024, then rose by 0.51% to $911.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $911.5 million in Q4 2025, $849.2 million in Q3 2025, and $882.3 million in Q2 2025.